Related Experiment Videos
Intravenous immunoglobulin as therapy for pediatric Guillain-Barré syndrome
S A Abd-Allah1, P W Jansen, S Ashwal
1Department of Pediatrics, Loma Linda University Children's Hospital, CA 92350, USA.
Insights
Intravenous immunoglobulin (IVIG) offers effective treatment for pediatric Guillain-Barré syndrome, showing comparable clinical results to plasmapheresis but with fewer pediatric intensive care unit admissions and shorter stays. IVIG is recommended as a preferred initial therapy.
Area of Science:
- Pediatric Neurology
- Immunology
- Critical Care Medicine
Background:
- Guillain-Barré syndrome (GBS) is a rare autoimmune disorder affecting the peripheral nervous system in children.
- Intravenous immunoglobulin (IVIG) and plasmapheresis are established treatments for GBS.
- Comparative data on IVIG versus plasmapheresis in pediatric GBS is limited.
Purpose of the Study:
- To evaluate the efficacy and safety of IVIG as an initial therapy for pediatric Guillain-Barré syndrome.
- To compare outcomes of IVIG treatment with historical data of plasmapheresis in a similar pediatric GBS cohort.
- To assess the impact of IVIG on pediatric intensive care unit (PICU) utilization.
Main Methods:
- Seven children with GBS received standard IVIG dosage (0.4 g/kg/day for 5 days).
- Clinical improvement, mechanical ventilation needs, and PICU admission/duration were recorded.
- Outcomes were compared to a historical cohort of eight children treated with plasmapheresis alone.
- Literature review identified 74 additional pediatric GBS cases treated with IVIG.
Main Results:
- Clinical improvement was observed within 2.4 days of initiating IVIG.
- One child required mechanical ventilation for 7 days.
- The IVIG group had significantly lower PICU admission rates and shorter PICU stays compared to the plasmapheresis group (P < .05).
- No major complications were noted with IVIG, except transient hypotension in one patient.
Conclusions:
- Intravenous immunoglobulin is an effective and safe initial treatment for pediatric Guillain-Barré syndrome.
- IVIG demonstrates comparable efficacy to plasmapheresis with a better safety profile regarding PICU utilization.
- IVIG is recommended as a preferred first-line therapy for pediatric GBS due to its efficacy and reduced complications.
Abstract:
Seven children with Guillain-Barré syndrome were treated with intravenous immunoglobulin. Median patient age was 5.8 years. A standard dosage of 0.4 g/kg/day for 5 days was administered. Clinical improvement occurred on average within 2.4 +/- 1.3 days of beginning intravenous immunoglobulin. One child required mechanical ventilation for 7 days. Eight comparable children with Guillain-Barré syndrome at our institution in a prior study treated with plasmapheresis alone had similar clinical results. However, the need for admission to the pediatric intensive care unit and duration of pediatric intensive care unit stay were lower in the intravenous immunoglobulin treated group (P < .05). There were no complications with intravenous immunoglobulin therapy except for a brief episode of hypotension in one patient. Review of the literature identified 74 additional children with Guillain-Barré syndrome successfully receiving intravenous immunoglobulin therapy. We suggest intravenous immunoglobulin as initial therapy for pediatric Guillain-Barré syndrome, because it appears equally as effective as plasmapheresis and is associated with fewer complications.